全文获取类型
收费全文 | 538篇 |
免费 | 105篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 19篇 |
妇产科学 | 58篇 |
基础医学 | 17篇 |
口腔科学 | 5篇 |
临床医学 | 227篇 |
内科学 | 103篇 |
皮肤病学 | 11篇 |
神经病学 | 17篇 |
特种医学 | 18篇 |
外科学 | 61篇 |
综合类 | 4篇 |
预防医学 | 45篇 |
眼科学 | 2篇 |
药学 | 7篇 |
肿瘤学 | 46篇 |
出版年
2024年 | 4篇 |
2023年 | 27篇 |
2022年 | 10篇 |
2021年 | 23篇 |
2020年 | 23篇 |
2019年 | 9篇 |
2018年 | 40篇 |
2017年 | 44篇 |
2016年 | 43篇 |
2015年 | 42篇 |
2014年 | 49篇 |
2013年 | 36篇 |
2012年 | 26篇 |
2011年 | 16篇 |
2010年 | 23篇 |
2009年 | 49篇 |
2008年 | 10篇 |
2007年 | 17篇 |
2006年 | 21篇 |
2005年 | 3篇 |
2004年 | 11篇 |
2003年 | 5篇 |
2002年 | 4篇 |
2001年 | 11篇 |
2000年 | 2篇 |
1999年 | 5篇 |
1998年 | 15篇 |
1997年 | 16篇 |
1996年 | 13篇 |
1995年 | 5篇 |
1994年 | 4篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1971年 | 2篇 |
排序方式: 共有645条查询结果,搜索用时 15 毫秒
91.
Elissa M. Ozanne PhD rea Loberg Sherwood Hughes Christine Lawrence Brian Drohan MS Alan Semine MD Michael Jellinek MD Claire Cronin MD Frederick Milham MD MBA Dana Dowd RN NP Caroline Block MD Deborah Lockhart John Sharko MS Georges Grinstein PhD Kevin S. Hughes MD 《The breast journal》2009,15(2):155-162
Abstract: Despite advances in identifying genetic markers of high risk patients and the availability of genetic testing, it remains challenging to efficiently identify women who are at hereditary risk and to manage their care appropriately. HughesRiskApps, an open-source family history collection, risk assessment, and Clinical Decision Support (CDS) software package, was developed to address the shortcomings in our ability to identify and treat the high risk population. This system is designed for use in primary care clinics, breast centers, and cancer risk clinics to collect family history and risk information and provide the necessary CDS to increase quality of care and efficiency. This paper reports on the first implementation of HughesRiskApps in the community hospital setting. HughesRiskApps was implemented at the Newton-Wellesley Hospital. Between April 1, 2007 and March 31, 2008, 32,966 analyses were performed on 25,763 individuals. Within this population, 915 (3.6%) individuals were found to be eligible for risk assessment and possible genetic testing based on the 10% risk of mutation threshold. During the first year of implementation, physicians and patients have fully accepted the system, and 3.6% of patients assessed have been referred to risk assessment and consideration of genetic testing. These early results indicate that the number of patients identified for risk assessment has increased dramatically and that the care of these patients is more efficient and likely more effective. 相似文献
92.
93.
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma
下载免费PDF全文

94.
L-alpha-Glycerol-3-phosphate dehydrogenase (EC 1.1.1.8) has been reported to be absent in the erythrocytes of normal adults, but can be found in those of cord blood and of thalassemia major. The aid of this study was to investigate whether there is any relation between GDH and gamma-chain synthesis. Erythrocyte GDH activity was determined on 118 different blood samples. It was undetectable in normal adult erythrocytes and definitely high in cord blood cells (23.6 UI/10(11) RBC). Considerable GDH activity was also noted in patients with thalassemia major (11.0 IU10(11) RBC) as well as in cases with pronounced reticulocytosis (11.4 IU/10(11) RBC). Red cells from beta- thalassemia heterozygotes exhibited moderate but distinct GDH activity (5.2 IU/10(11) RBC). After fractionation into young and old erythrocyte populations, clearly higher GDH activity was found in the younger cells; however, there was no significant correlation with the reticulocyte count. Presence of reticulocytes alone appears insufficient to explain the values obtained in cord blood and the thalassemias, especially heterozygous. Furthermore, no direct correlation between GDH and fetal hemoglobin (HbF) was obtained in cord and thalassemic erythrocytes. 相似文献
95.
JK Gass SK Chan E Rytina DC Greenberg NP Burrows 《Journal of the European Academy of Dermatology and Venereology》2010,24(5):601-603
Background Merkel cell carcinoma (MCC) is a rare malignant cutaneous tumour, the incidence of which is increasing. Second malignancies have been reported to occur with high incidence in these patients. Objectives We report the rate and nature of multiple malignancies in patients with MCC treated over a 10 year period in Addenbrooke’s Hospital in Cambridge, United Kingdom, as well as the temporal relationship of these additional malignancies to the diagnosis of MCC. Results The 27 patients had an approximately equal sex incidence with a median age at diagnosis of 79 years. Seventy percent (n=19) of patients had a second primary malignant tumour; and 7 of these patients had two or more tumours in addition to the MCC. Eighteen patients had additional cutaneous malignancies: melanoma, squamous cell carcinoma and basal cell carcinoma, and 8 patients presented non‐cutaneous malignancy including colorectal, haematological and breast tumours. Of the 28 additional tumours in our patients, half were diagnosed prior to presentation of MCC, 32% within 6 months of diagnosis, and 18% between 6 months and 3 years after diagnosis. Possible reasons for the high rate of additional tumours in this population are discussed. Conclusions Our figures reflect a higher incidence of multiple malignancies in those with Merkel cell tumour than has previously been reported. This has important implications for the care and surveillance of these patients. 相似文献
96.
A nurse practitioner (NP) program to improve postpartum appointment keeping in an outpatient family planning clinic is described and evaluated. The subjects (N = 59) were non-high-risk obstetric patients prescheduled to be seen at 6 weeks postpartum by the NP. Two groups were identified by convenience sampling: Group A (n = 25), the nonintervention group, and Group B (n = 34), the intervention group. Two types of intervention were used: a postpartum telephone call after discharge (n = 11), or a predischarge postpartum visit (n = 23). Results suggest that those in the intervention group were more likely to keep their appointments (p less than .02); only the postpartum visit increased the probability of appointment keeping (p less than .05). 相似文献
97.
Phase 2 trial of high‐dose rituximab with high‐dose cytarabine mobilization therapy and high‐dose thiotepa,busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non‐Hodgkin lymphoma
下载免费PDF全文

Yi‐Bin Chen MD Tracy Batchelor MD MPH Shuli Li MD Ephraim Hochberg MD Mark Brezina MD Sooae Jones NP Candice Del Rio RN Morgan Curtis MD Karen K. Ballen MD Jeffrey Barnes MD PhD Andrew S. Chi MD PhD Jorg Dietrich MD PhD Jessica Driscoll NP Elizabeth R. Gertsner MD Fred Hochberg MD Ann S. LaCasce MD Steven L. McAfee MD Thomas R. Spitzer MD Lakshmi Nayak MD Philippe Armand MD PhD 《Cancer》2015,121(2):226-233
98.
Aleli Campbell MS Rosalinda Heydarian NP Cecilia Ochoa MPH Alok Kumar Dwivedi PhD Zeina A. Nahleh MD 《The breast journal》2018,24(3):260-268
Breast cancer patients receiving endocrine therapy with aromatase Inhibitors (AIs) often experience musculoskeletal and joint‐related side effects. The purpose of this study was to evaluate the effect of Vitamin B12 supplements on musculoskeletal symptoms such as pain and arthralgias induced by AIs and to correlate response with serum and inflammatory biomarkers. Upon receiving approval by the Institutional Review Board (IRB), the majority of the patients consented into the study were treated at the Texas Tech Breast Care Center. Included were patients who had a diagnosis of invasive breast cancer (Stages I‐III), and were experiencing significant musculoskeletal symptoms associated to AIs. Only patients with an average pain score ≥ 4, as assessed by the Brief Pain Inventory‐Short Form (BPI‐SF) questionnaire, were included in the study. Participants received 2500 mcg of sublingual vitamin B12 daily for 90 days. Assessments at baseline and at 3 months included: BPI‐SF pain scores, the impact on quality of life determined by Functional Assessment of Cancer Therapy–Endocrine Symptoms (FACT‐ES), and correlative serum markers relative to baseline (a pre‐post study). A total of forty‐one patients were enrolled. Average pain scores were improved by 34% (P < .0001) at 3 months compared to baseline. In addition, a 23% improvement in worst pain was noted (P = .0003). Analysis of the results for the FACT‐ES scoring showed improvement on all scales. No significant adverse events were observed. Decrease in pain score was correlated with increased serum B12 levels. This study suggests that Vitamin B12 reduces pain and improves quality of life for patients taking AIs who experienced AI‐related musculoskeletal symptoms. If confirmed in large randomized prospective trials, Vitamin B12 would be a safe and cost‐effective option for the treatment of AI‐related musculoskeletal symptoms. 相似文献
99.
100.